Business
Tandem Diabetes Care Announces Third Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its
About this update from Tandem Diabetes Care, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nTandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full year 2025 guidance.\n\nThird Quarter 2025 and Recent Highlights\n\n\nAchieved record third quarter sales both in the United States (U.S.) and internationally\n\n\nDemonstrated year-over-year and sequential gross margin improvement\n\n\nProgressed multi-channel initiative by:\n\n\nIncreasing pharmacy benefit coverage for Tandem Mobi to more than 40% of U.S. lives\n\n\nIntroducing t:slim X2 supplies through a pharmacy benefit\n\n\n\n\nReceived 510(k) clearance from the U.S. Food and Drug Administration (FDA) for extended wear use of the SteadiSet Infusion Set\n\n\nFiled a 510(k) with the FDA for Android mobile control of the Tandem Mobi insulin delivery system\n\n\nBegan global commercial rollout of t:slim X2 pump integration with the FreeStyle Libre 3 Plus CGM sensor\n\n\n“Tandem delivered a strong third quarter performance marked by record quarterly sales, significant gross margin improvement, and meaningful progress on our key strategic initiatives,” said John Sheridan, president and chief executive officer. “We are beginning to see the positive impact of our business transformation, which strengthens our ability to achieve Tandem’s near- and longer-term goals, while continuing our commitment to improve the lives of people with diabetes.”\n\nThird Quarter 2025 Results Compared to Third Quarter 2024\n\n\nSales (1): Worldwide sales increased to $249.3 million, which included sales outside the United States of $73.6 million. This is compared to worldwide sales of $244.0 million, which included sales of $72.3 million outside the United States.\n\nNon-GAAP worldwide sales(2) of increased to $249.3 million, which included sales outside of the United States of $73.6 million. This is compared to worldwide sales of $242.9 million, which included sales of $72.3 million outside the United States.\n\nShipments in the United States were more than 20,000 pumps. Shipments outside the United States were more than 9,000 pumps.\n\n\n\n\nGross profit (1): GAAP gross profit was $134.3 million, compared to $124.7 million. GAAP gross margin was 54%, compared to 51%.\n\nNon-GAAP gross profit(2) was $134.3 million, compared ...